CA-C3.AI
C3 AI today announced that it was awarded a broad-ranging omnibus patent for the company’s end-to-end enterprise AI solution, C3 AI® Suite, further solidifying the company’s position as a leading enterprise AI software provider for accelerating digital transformation, as well as strengthening C3 AI’s intellectual property and competitive advantage.
The newly issued U.S. patent (No.10,817,530) was granted for “systems, methods, and devices for an enterprise AI application development platform.” The patent encompasses not only advanced data processing and AI application development, but also the extensive array of techniques necessary to build an end-to-end enterprise AI platform, including C3 AI’s unique model-driven architecture.
“This patent is the most significant and substantial we have been awarded to date,” said Thomas M. Siebel, CEO of C3 AI. "When we filed years ago, no one else conceived of a comprehensive, end-to-end solution with a model-driven architecture that accelerates the delivery and reduces the complexity of developing and operating enterprise AI applications. This sweeping patent further extends our leadership and maturity in this market as well as our commitment to protect our IP and our customers, ensuring their ability to rapidly deploy and scale AI with confidence to drive high-value outcomes across their business."
The comprehensive patent protects many methods and techniques that enable the development of enterprise AI applications, including:
- Use of a model-driven architecture for the “design, development, deployment, and operation of next-generation cyber-physical software applications and business processes”
- The “application of advanced data aggregation methods, data persistence methods, data analytics, and machine learning methods”
- Methods for “implementing abstraction and continuous processing of the aggregated data using a model-driven architecture”
- Embedding capabilities “in a model-driven architecture type system to recommend actions based on real-time analysis of petabyte-scale data sets and telemetry data from millions to billions of endpoints”
- The use of an ontology, or canonical data mode, that “comprises conceptual domain models of various attributes and processes related to different entities or domains,” wherein “the various attributes and processes comprise persistence, data representations, data interrelationships, computing processes, or machine learning algorithms” and “is extensible to allow users of said application development platform to integrate new data formats”
- A standardized data format that “comprises an aggregation and correlation of two or more data formats associated with the plurality of data stores, while ensuring automatic and guaranteed referential integrity of the underlying two or more data formats,” wherein “the standardized data format is automatically exposed and accessible through RESTful interfaces”
- “A method comprising: storing time-series data in a key-value store and non-time-series data in a relational database; implementing, on an application development platform, abstraction over a plurality of data stores comprising the key-value store and the relational database, wherein the abstraction comprises a metadata-based mapping framework over a plurality of data formats associated with the plurality of data stores.”
“This appears to be a seminal patent,” said Bruce Sewell, a C3 AI director, and former general counsel of Apple and Intel. “A close reading reveals a number of fundamental concepts that appear both necessary and sufficient to deploy an enterprise AI application.”
C3 AI has invested over a decade building a leading platform that brings enterprise AI solutions across industries at global, industrial scale to drive digital transformation. The C3 AI Suite is a scalable, production-ready enterprise AI solution that enables organizations to rapidly design, develop, and deploy enterprise-scale AI applications on any public, private, or hybrid cloud environment. It allows organizations to integrate and unify massive, fragmented data sets from disparate enterprise and extraprise data stores and sensors, and apply machine learning algorithms to generate predictive insights that improve efficiency, reduce costs, increase revenue, enhance safety, and drive greater profitability.
At the core of the C3 AI Suite is an open, model-driven architecture that significantly simplifies and accelerates data science and the development of enterprise AI applications – from data integration and data management to model development, validation, and deployment. With C3 AI’s model-driven architecture, a small team of developers can build and deploy enterprise-class AI applications in a matter of weeks, with up to 99 percent less code compared to other methods, by using conceptual models of all the elements an application requires.
C3 AI is establishing a Technology Licensing Office to enable third parties to license C3 AI-patented technologies for use in their own products and solutions.
This new patent follows the issue of a patent awarded for advanced methods of data processing. C3 AI holds additional patents in the areas of cybersecurity, fraud detection, and energy data processing.
Patent details are available in the United States Trademark and Patent Office database .
About C3.ai, Inc.
C3.ai, Inc. (NYSE: AI) is a leading provider of enterprise AI software for accelerating digital transformation. C3 AI delivers a family of fully integrated products: C3 AI® Suite, an end-to-end platform for developing, deploying, and operating large-scale AI applications; C3 AI Applications, a portfolio of industry-specific SaaS AI applications; C3 AI CRM, a suite of industry-specific CRM applications designed for AI and machine learning; and C3 AI Ex Machina, a no-code AI solution to apply data science to everyday business problems. The core of the C3 AI offering is an open, model-driven AI architecture that dramatically simplifies data science and application development. Learn more at: www.c3.ai
View source version on businesswire.com: https://www.businesswire.com/news/home/20210225005304/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release
Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release
- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and
Leading Global Scientists Gather at Tengchong Scientists Forum to Explore Innovative Pathways in Frontier Technologies6.12.2025 12:31:00 CET | Press release
The 2025 Tengchong Scientists Forum opened on Saturday in southwest China’s Yunnan Province, convening leading scientists and academic figures to examine innovation across frontier fields including artificial intelligence, biodiversity and quantum technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251205499197/en/ Opening ceremony of Tengchong Scientists Forum on 6th December, 2025 Notable participants include Nobel Physics laureate Konstantin Novoselov, Fields Medalist Efim Zelmanov and Turing Award winner Andrew Chi-Chih Yao, who join 127 academicians, 77 university presidents from China and abroad, over 400 scholars and more than 600 entrepreneurs and financiers. The gathering aims to deepen collaboration between cutting-edge research and industrial development. Under the theme “Science · AI changing the World,” the forum features ten sub-forums, academic sessions and thematic events supporting major cooperation p
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
